Albany, NY -- (SBWIRE) -- 03/13/2017 -- Global Intravenous Immunoglobulin (IVIG) Market: Snapshot
The global market for intravenous immunoglobulin (IVIG) products and therapies is heading in a positive direction due to several innovative techniques and advantages it offers to clinicians worldwide. The market is expected to expand at a healthy pace in the near future. Factors that will support market's growth include technological improvements in the methods used for production and purification of IVIG products and an improving health care infrastructure across the globe. The rising patient pool suffering from immunological and neurological disorders, mounting geriatric population, and rising production of IVIG products are also expected to have a significant positive impact on market's future growth prospects.
Transparency Market Research estimates that the market will exhibit a healthy 8.5% CAGR over the period between 2016 and 2024. Expanding at this pace, the market, which valued at US$7.23 bn in 2015, is expected to reach US$14.92 bn in 2024.
Intravenous Immunoglobulin Market : Key Players
Some of the key vendors operating in the highly consolidated global IVIG market are Baxalta Incorporated, Biotest AG, CSL Behring LLC, China Biologic Products, Inc., Grifols S.A., LFB Biomedicaments S.A., Kedrion S.p.A., Octapharma AG, and Sanquin Plasma Products B.V.
Browse full report on Intravenous Immunoglobulin Market -
Hospitals to Retain Dominance but Lose Promise to Home Care
In terms of end users of IVIG infusion therapy and products, the global IVIG market is segmented into hospitals, clinics, and home care settings. Of these, the hospitals segment is presently the dominant end user of the intravenous immunoglobulin (IVIG) market. A continuous rise in the number of patients opting for hospitals rather than clinics is the major driver of the hospitals segment. High budgetary expenditure, rising government investment, and better reimbursement policies also augment the number of patients opting hospitals for intravenous immunoglobulin (IVIG) therapies.
IVIG infusion therapy is a time consuming procedure, in which the infusion takes place at a slow rate and lasts for a long period of time. This factor is also expected to increase consumer preference to home care settings for treatment. Although the hospitals segment will continue to lead the global IVIG market, the rising inclination to home care is expected to make home care the most lucrative end-user segment of the intravenous immunoglobulin (IVIG) market over the forecast.
Market in North America to Continue to Remain Highly Lucrative
North America is presently the dominant regional market for intravenous immunoglobulin (IVIG) and is likely to witness significant growth during the forecast period as well. In the U.S., North America's most lucrative IVIG market, the demand for IVIG infusion therapy is driven by the country's strong economy, advancements in technology, abundant plasma supply, and rising prevalence of immunological disorders. Other factors ascribable to market growth include the favorable reimbursement policies, high investments in research and development, and increasing geriatric population in the country.
FDA's approval for payments to plasma donors to encourage plasma donation and boost yield is another major factor driving the IVIG market in the U.S. This has helped the country to not only become self-sufficient in plasma supply, but also a major exporter of plasma derived products globally, consecutively strengthening the North America market.
The IVIG market in Europe is also witnessing strong growth owing to increasing patient pool and geriatric population. Higher acceptance of innovative technologies and launch of new products in the region are also driving the IVIG market. Additionally, the ongoing clinical development of new products is anticipated to boost market growth during the forecast period. Asia Pacific is expected to be a promising market for intravenous immunoglobulin (IVIG) due to developing economies and presence of large underserved patient population. The number of patients suffering from immunological diseases is also high in the region, naturally increasing the demand for intravenous immunoglobulin products and therapies.
Request for sample of this report -